Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

J Kenneth Zuerblis


  • Director at Stemline Therapeutics Inc (STML), 2020-06-10
  • Evp, Chief Financial Officer at Savient Pharmaceuticals Inc (SVNT), 2012-02-13
  • Director at Immunomedics Inc (IMMU), 2011-12-09
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
STML $11.14 1,000 Director 11,963 2014-09-02 Filing
STML $16.38 700 Director 10,963 2013-05-30 Filing
STML $16.38 200 Director 10,263 2013-05-30 Filing
STML $15.86 1,000 Director 10,063 2013-05-29 Filing
STML $15.86 500 Director 9,063 2013-05-29 Filing